Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. OBJECTIVES: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. METHODS: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. RESULTS: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. CONCLUSIONS: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. OBJECTIVES: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. METHODS: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. RESULTS: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. CONCLUSIONS: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.
Authors: Ann Janssens; Zwi N Berneman; Fritz Offner; Sylvia Snauwaert; Philippe Mineur; Gaetan Vanstraelen; Stef Meers; Isabelle Spoormans; Dominique Bron; Isabelle Vande Broek; Charlotte Van Bogaert; Birgit De Beleyr; Ann Smet; Lasse Nielsen; Robert Wapenaar; Marc André Journal: Clin Hematol Int Date: 2022-10-13
Authors: Inhye E Ahn; Carsten U Niemann; Christian Brieghel; Kathrine Aarup; Mathias H Torp; Michael A Andersen; Christina W Yde; Xin Tian; Adrian Wiestner Journal: Clin Cancer Res Date: 2021-05-07 Impact factor: 13.801
Authors: Emelie C Rotbain; Klaus Rostgaard; Michael A Andersen; Caspar Da Cunha-Bang; Carsten U Niemann; Henrik Frederiksen; Henrik Hjalgrim Journal: Clin Epidemiol Date: 2021-12-30 Impact factor: 4.790
Authors: Soo Jin Seung; Manjusha Hurry; Shazia Hassan; Ashlie Elnoursi; Krystin A B Scheider; Dennis Wagner; Jonathan J Edwin; Andrew T W Aw Journal: Curr Oncol Date: 2021-11-19 Impact factor: 3.677
Authors: Caroline Dartigeas; Borhane Slama; Margaret Doyle; Christoph Tapprich; Claire Albrecht; Sandrine Dupuis; Robert Wapenaar; Charlotte Schmidt-Hieber; Veronique Leblond Journal: Clin Hematol Int Date: 2022-09-14